Our Q1 2025 financial results
April 24, 2025
Merck’s (NYSE: MRK) Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion.
“Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman and chief executive officer. “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”
Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion.
Take a look at the infographic below for more details on Q1 2025 results.
